Antimicrobial Drugs: Mechanisms, Applications, and Resistance

Antimicrobial Drugs: Basic Principles

Introduction to Antimicrobial Drugs

Antimicrobial drugs are compounds used to kill or inhibit the growth of microorganisms, revolutionizing modern medicine by enabling effective treatment of infectious diseases. Their discovery and development have significantly reduced mortality from infections that were once fatal.

• Alexander Fleming discovered penicillin in 1928 from the mold Penicillium, which inhibited Staphylococcus aureus growth.

• Streptomycin was isolated from Streptomyces griseus and proved effective against tuberculosis.

• Antimicrobial drugs are classified by the pathogens they target: antibacterial, antiviral, antifungal, and antiparasitic.

Key Terms and Classifications

• Antibiotic: Naturally occurring antimicrobial compound.

• Antimicrobial drug: Includes antibiotics and synthetic/semisynthetic compounds.

• Broad-spectrum: Effective against a wide range of bacteria (both Gram-positive and Gram-negative).

• Narrow-spectrum: Targets a limited range of bacteria; preferred to minimize disruption of normal microbiota.

• Bacteriostatic: Inhibits bacterial growth; often targets protein synthesis or metabolic pathways.

• Bactericidal: Kills bacteria; often targets cell walls, membranes, or nucleic acids.

• Natural, semisynthetic, synthetic: Refers to the origin and chemical modification of drugs.

Drug Safety and Development

Drug development requires careful consideration of safety, efficacy, and pharmacokinetics.

• Therapeutic index: Ratio of maximum tolerated dose to minimum effective dose. High index = safer drug.

• Selective toxicity: Drug targets microbial processes not found in human cells.

• Drug half-life: Time for half the drug to be eliminated; affects dosing frequency.

• Hepatotoxicity: Liver damage risk; e.g., some antimicrobials cause drug-induced liver injury (DILI).

• Nephrotoxicity: Kidney damage risk; aminoglycosides and NSAIDs are common causes.

• Administration routes: Oral (preferred), parenteral (injection), each with specific requirements and drawbacks.

• Drug interactions and contraindications: E.g., rifampin inactivates oral contraceptives; tetracyclines contraindicated in pregnancy.

Survey of Antibacterial Drugs

Beta-Lactam Drugs

Beta-lactam drugs inhibit bacterial cell wall synthesis by blocking transpeptidase enzymes, preventing peptidoglycan cross-linking.

• Penicillins: Natural and semisynthetic; effective against Gram-positive, some Gram-negative. Examples: Penicillin G (injectable), Penicillin V (oral), amoxicillin, ampicillin.

• Cephalosporins: Broad-spectrum, five generations; later generations more active against Gram-negative, less against Gram-positive. Used for penicillin-allergic patients.

• Carbapenems: Broad-spectrum, reserved for multidrug-resistant infections. Examples: imipenem, meropenem.

• Monobactams: Single-ring structure; aztreonam is effective against Gram-negative bacteria.

• Beta-lactamase inhibitors: Clavulanate, sulbactam, tazobactam; combined with beta-lactams to combat resistance.

Non-Beta-Lactam Cell Wall Inhibitors

• Glycopeptides: E.g., vancomycin, teicoplanin; effective against Gram-positive, including MRSA. Not absorbed orally for systemic infections.

• Bacitracin: Polypeptide, topical use for Gram-positive bacteria.

• Isoniazid: Used for tuberculosis; inhibits mycolic acid synthesis in acid-fast bacteria.

Drugs Targeting Nucleic Acid Synthesis

• Quinolones (fluoroquinolones): Synthetic, target DNA gyrase/topoisomerase. Examples: ciprofloxacin, levofloxacin.

• Rifamycins: Inhibit RNA polymerase; rifampin is broad-spectrum, effective against mycobacteria.

Antifolate Drugs

• Sulfa drugs (sulfonamides): Competitive inhibitors of folic acid synthesis; do not affect human cells. Often combined with trimethoprim for synergism.

Protein Synthesis Inhibitors

• Macrolides: Target 50S ribosomal subunit; examples: erythromycin, azithromycin.

• Lincosamides: Target 50S; clindamycin effective against MRSA, risk of C. difficile colitis.

• Phenicols: Target 50S; chloramphenicol reserved for severe infections due to toxicity.

• Tetracyclines: Target 30S; broad-spectrum, not for children under 8.

• Aminoglycosides: Target 30S; narrow-spectrum, risk of nephrotoxicity and hearing loss.

Polypeptide Drugs Targeting Membranes

• Polymyxin B, colistin: Destabilize Gram-negative cell membranes; used topically or intravenously for multidrug-resistant infections.

Drugs for Viral and Eukaryotic Infections

Antiviral Drugs

Antiviral drugs target specific stages of viral replication: attachment, penetration, uncoating, replication/assembly, release, or stimulate immune responses (e.g., interferons).

• Most effective against actively replicating viruses; latent viruses are difficult to treat.

• Examples: HIV, herpes, hepatitis, influenza, COVID-19 (Remdesivir).

Antifungal Drugs

• Azoles, allyamines: Inhibit ergosterol synthesis; treat athlete’s foot, ringworm, yeast infections.

• Polyenes: Interact with ergosterol, cause membrane leakage; nystatin (topical), amphotericin B (systemic).

• Echinocandins: Inhibit beta-glucan synthesis in cell walls; used for systemic infections.

• Flucytosine: Inhibits nucleic acid synthesis; used with amphotericin B.

Antiprotozoan and Antihelminthic Drugs

• Antimalarial drugs: Aminoquinolines (chloroquine), artemisinins, antifolates, etc.

• Nonmalarial antiprotozoan drugs: Metronidazole, TMP/SMX, nitazoxanide.

• Antihelminthic drugs: Albendazole, mebendazole (target microtubules), praziquantel (paralyzes parasites).

Assessing Sensitivity to Antimicrobial Drugs

Antibiotic Susceptibility Testing

Testing is essential to determine the most effective drug for a pathogen.

• Kirby-Bauer test: Disk diffusion; measures zone of inhibition.

• E-test: Strip with drug gradient; determines minimum inhibitory concentration (MIC).

• Broth dilution test: Serial dilutions; determines MIC and minimum bactericidal concentration (MBC).

Drug Resistance and Stewardship

Antimicrobial Resistance

Resistance occurs when microbes are unaffected by intended drug therapy. Superbugs are resistant strains that can cause superinfections.

• Intrinsic resistance: Natural, e.g., Mycoplasma (no cell wall), C. difficile (endospores), Gram-negative (outer membrane).

• Acquired resistance: Genetic mutations or acquisition of resistance genes.

Mechanisms of Resistance

• Target alteration: Mutation prevents drug binding (e.g., rifampin resistance).

• Drug inactivation: Enzymes break down or modify drugs (e.g., beta-lactamases).

• Reduced drug concentration: Limiting entry or efflux pumps remove drugs.

Human Behaviors and Resistance

• Noncompliance and misuse (missed doses, incomplete regimens, self-medication) accelerate resistance.

• Agricultural misuse (antibiotics in animal feed) and clinical misuse (inappropriate prescriptions) contribute to resistance.

• Healthcare settings are incubators for resistance due to high pathogen prevalence and drug use.

Combating Resistance

• Proper drug stewardship: hand hygiene, limiting unnecessary prescriptions, using narrow-spectrum drugs, patient education.

• Patients: follow dosing instructions, proper medication storage, avoid demanding antibiotics.

Challenges in Drug Development

• Drug development is costly, time-consuming, and economically challenging.

• Incentives include patent extensions and government subsidies.

• New approaches: multidrug combinations, resistance inhibitors, phage therapy.

Visual Summary

Clinical Case Example

Case Study: Walking Pneumonia and C. difficile Relapse

• Patient with penicillin allergy treated with azithromycin for walking pneumonia.

• Developed C. difficile infection after antibiotic therapy; treated with vancomycin.

• Relapse occurred, highlighting risks of broad-spectrum antibiotics and importance of proper stewardship.

Table: Summary of Key Antibacterial Drug Families

Drug Family	Mechanism	Spectrum	Examples	Notes
Penicillins	Cell wall synthesis inhibition	Gram-positive, some Gram-negative	Penicillin G, Penicillin V, amoxicillin	Beta-lactamase susceptible
Cephalosporins	Cell wall synthesis inhibition	Broad-spectrum	Ceftriaxone, ceftaroline	Five generations
Carbapenems	Cell wall synthesis inhibition	Broad-spectrum	Imipenem, meropenem	Reserved for MDR infections
Monobactams	Cell wall synthesis inhibition	Gram-negative	Aztreonam	Single ring structure
Glycopeptides	Cell wall synthesis inhibition	Gram-positive	Vancomycin, teicoplanin	MRSA, C. difficile
Quinolones	DNA replication inhibition	Broad-spectrum	Ciprofloxacin, levofloxacin	Reserved for resistant infections
Rifamycins	RNA synthesis inhibition	Broad-spectrum	Rifampin	Drug interactions
Sulfa drugs	Folic acid synthesis inhibition	Broad-spectrum	Sulfamethoxazole, TMP/SMX	Synergistic combinations
Macrolides	Protein synthesis inhibition (50S)	Broad-spectrum	Erythromycin, azithromycin	Alternative for penicillin allergy
Lincosamides	Protein synthesis inhibition (50S)	Broad-spectrum	Clindamycin	Risk of C. difficile colitis
Phenicols	Protein synthesis inhibition (50S)	Broad-spectrum	Chloramphenicol	Bone marrow toxicity
Tetracyclines	Protein synthesis inhibition (30S)	Broad-spectrum	Doxycycline, tetracycline	Not for children under 8
Aminoglycosides	Protein synthesis inhibition (30S)	Gram-negative	Gentamicin, streptomycin	Nephrotoxicity, hearing loss
Polypeptides	Membrane disruption	Gram-negative	Polymyxin B, colistin	Topical or IV for MDR infections

Key Equations

• Therapeutic Index: $\text{Therapeutic Index} = \frac{\text{Maximum Tolerated Dose}}{\text{Minimum Effective Dose}}$

• Drug Half-Life: $\text{Half-Life} = \frac{0.693}{k}$ (where $k$ is the elimination rate constant)